Valuation: CEL-SCI Corporation

Market Cap 2.95Cr 2.6Cr 2.45Cr 2.24Cr 4.18Cr 283.65Cr 4.21Cr 29Cr 11Cr 144.36Cr 11Cr 11Cr 469.77Cr P/E 2026 *
-0.55x
P/E 2027 * -0.26x
Enterprise Value 2.4Cr 2.11Cr 1.99Cr 1.82Cr 3.39Cr 230.34Cr 3.42Cr 24Cr 9.25Cr 117.23Cr 9.01Cr 8.81Cr 381.48Cr EV / Sales 2026 *
-
EV / Sales 2027 * 4.05x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-14.33% - - 2.95Cr
-3.30%+2.97%+54.99%+104.15% 7.42TCr
-0.12%-1.63%+33.14%+74.86% 5.96TCr
+2.71%-0.84%-16.39%+364.46% 2.58TCr
+0.81%+3.58%+1.01%-5.14% 2.47TCr
-1.05%+2.58%+24.27%-10.32% 2.09TCr
-1.70%-4.15%+147.82%+325.69% 1.53TCr
+2.15%+2.06%+45.57%+169.79% 1.41TCr
-0.43%-5.32%-14.46%+775.94% 1.31TCr
+0.04%-3.00%+15.76%+234.69% 1.19TCr
Average -0.12%-0.80%+32.41%+226.01% 2.88TCr
Weighted average by Cap. -0.71%-0.22%+34.92%+160.29%

Financials

2026 *2027 *
Net sales - 59.72L 52.53L 49.52L 45.18L 84.49L 57Cr 85.15L 5.94Cr 2.3Cr 29Cr 2.24Cr 2.19Cr 95Cr
Net income -2.51Cr -2.21Cr -2.08Cr -1.9Cr -3.55Cr -240.79Cr -3.58Cr -25Cr -9.67Cr -122.55Cr -9.42Cr -9.21Cr -398.78Cr -2.95Cr -2.6Cr -2.45Cr -2.23Cr -4.18Cr -283.31Cr -4.21Cr -29Cr -11Cr -144.19Cr -11Cr -11Cr -469.21Cr
Net Debt -55.54L -48.85L -46.05L -42.02L -78.58L -53Cr -79.19L -5.53Cr -2.14Cr -27Cr -2.09Cr -2.04Cr -88Cr -53.39L -46.96L -44.27L -40.39L -75.54L -51Cr -76.12L -5.31Cr -2.06Cr -26Cr -2Cr -1.96Cr -85Cr
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-